Cipla moves up on getting EIR from USFDA for Indore plant
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cipla is currently trading at Rs. 1071.00, up by 9.30 points or 0.88% from its previous closing of Rs. 1061.70 on the BSE.
The scrip opened at Rs. 1065.00 and has touched a high and low of Rs. 1092.80 and Rs. 1065.00 respectively. So far 28305 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1101.00 on 21-Sep-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021.
Last one week high and low of the scrip stood at Rs. 1101.00 and Rs. 1015.05 respectively. The current market cap of the company is Rs. 87672.65 crore.
The promoters holding in the company stood at 33.61%, while Institutions and Non-Institutions held 48.98% and 17.40% respectively.
Cipla has received the Establishment Inspection Report (EIR) for its Indore plant, indicating closure of the inspection. The United States Food and Drug Administration (USFDA) had conducted product-specific pre-approval inspection (PAI) at the Indore plant on June 27 and July 1.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
